Results 111 to 120 of about 37,793 (186)

Investigation of the nephrotoxicity of remdesivir \(in\) \(vitro\)

Aufgrund von Nierenschädigung im Tiermodell und klinischen Sicherheitsbedenken bezüglich der Anwendung von Remdesivir bei Covid-19-Patienten mit der Gefahr von Nierenfunktionsstörung bis hin zum Nierenversagen im Vergleich zu anderen antiviralen ...
Breunig, Leonie
core   +1 more source

Remdesivir inhibits endothelial activation and atherosclerosis by coupling TAL1 to TRAF6

Journal of Translational Medicine
Background Atherosclerosis is characterized by complex pathological processes, including endothelial dysfunction and inflammation. The underlying pathogenic mechanisms have been well elucidated; however, effective treatments are yet to be validated.
Hanning Zhang, Ruru Li, Qianqian Huo, Li Li, Min Li, Shunxin Hu, Changjie Ren, Zongyin Wu, Chenghu Zhang   +8 more
doaj   +1 more source

Remdesivir como tratamiento para COVID-19

, 2021
Introduction: The SARS-CoV-2 coronavirus was initially detected at the end of 2019, there is no specific drug established for the treatment and due to its homology with the SARS virus, remdesivir has been considered as a therapeutic option.
Bustillos, Alberto, Yépez, Solmayra
core  

The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load

Scientific Reports
The impact of remdesivir on renal and liver functions remains a matter of concern in advanced COVID-19 patients with high illness severity and presence of viral load.
Petr Waldauf, Ivana Jurisinova, Eva Svobodova, Michaela Diblickova, Tomas Tencer, Jan Zavora, Gabriela Smela, Lenka Kupidlovska, Vaclava Adamkova, Marta Fridrichova, Karolina Jerabkova, Jakub Mikes, Frantisek Duska, Ladislav Dusek, Martin Balik   +14 more
doaj   +1 more source

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance

Viruses
Various SARS-CoV-2 remdesivir resistance-associated substitutions (RAS) have been reported, but a comprehensive comparison of their resistance levels is lacking.
Carlota Fernandez-Antunez, Line A. Ryberg, Kuan Wang, Long V. Pham, Lotte S. Mikkelsen, Ulrik Fahnøe, Katrine T. Hartmann, Henrik E. Jensen, Kenn Holmbeck, Jens Bukh, Santseharay Ramirez   +10 more
doaj   +1 more source

The impact of remdesivir on SARS-CoV-2 evolution in vivo

JCI Insight
The impact of remdesivir on SARS-CoV-2 diversity and evolution in vivo has remained unclear. In this single-center, retrospective cohort study, we assessed SARS-CoV-2 diversification and diversity over time in a cohort of hospitalized patients who did or
Ted Ling-Hu, Lacy M. Simons, Estefany Rios-Guzman, Alexandre Machado Carvalho, Maria Francesca R. Agnes, Arghavan Alisoltanidehkordi, Egon A. Ozer, Ramon Lorenzo-Redondo, Judd F. Hultquist   +8 more
doaj   +1 more source

Remdesivir for the treatment of COVID-19 — Final report

, 2020
BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.
Kalil, A.C., Dierberg, K., Fätkenheuer, G., Dodd, L.E., Beigel, J.H., Makowski, M., Chu, H.Y., Green, M., Babiker, A.G., for the ACTT-1 Study Group Members, Lye, D.C., Atmar, R.L., Neaton, J.D., Finberg, R.W., de Castilla, D.L., Paredes, R., Bonnett, T., Ohmagari, N., Benfield, T., Pett, S., Hohmann, E., Tomashek, K.M., Luetkemeyer, A., Creech, C.B., Sweeney, D.A., Short, W.R., Lundgren, J., Nayak, S., Mehta, A.K., Ruiz-Palacios, G.M., Hsieh, L., Oh, M.-D., Kortepeter, M.G., Touloumi, G., Zingman, B.S., Osinusi, A., Tapson, V., Lane, H.C., Kline, S., Patterson, T.F., Burgess, T.H.   +40 more
core  

Ficha técnica RACIM : Remdesivir

, 2020
Informe CIMEFil: Nuñez Montoya, Susana Carolina. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Ciencias Farmacéuticas; Argentina.Al ser un análogo de nucleótido de ARN interfiere con la polimerización del ARN del virus ...
Nuñez Montoya, Susana Carolina
core  

Incidence of COVID-19 Symptom Rebound After Treatment with Remdesivir

Background/Objectives: Recent in vitro data suggest that remdesivir might be less likely than nirmatrelvir–ritonavir to be associated with COVID-19 rebound.
Rebecca Madjarov, Judith Strymish, William J. O’Brien, Anna Chen, Michael E. Charness, Kalpana Gupta, Katherine Linsenmeyer   +6 more
core   +1 more source

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19

Severe acute respiratory syndrome coronavirus 2 has infected millions of people, but about 20% of infected individuals do not develop symptoms. COVID-19 is an inflammatory disease that affects a portion of individuals infected with the virus and it is ...
Alireza FakhriRavari, Mazyar Malakouti
core   +1 more source